atilmotin

Atilmotin is a **synthetic peptide analog of motilin** and acts as a potent, short-acting **motilin receptor agonist** under investigation for the treatment of gastrointestinal motility disorders, in particular **postoperative ileus** and potentially other stomach motility disorders such as gastroparesis. Its main mechanism is to **stimulate motilin receptors** (GPR38) in the upper GI tract, thereby **increasing gastric and lower esophageal sphincter (LES) pressure** and accelerating gastric emptying. The drug is administered intravenously, has a plasma half-life of less than 10 minutes, and demonstrates a rapid onset and short duration of action. Preclinical and Phase 1/2 clinical studies showed it increases initial gastric emptying of solids and liquids, increases LES pressure, and can cause esophageal contraction disruptions at higher doses. Its most advanced clinical development status was Phase 2 for gastrointestinal motility disorders, but development has been discontinued. No serious adverse effects were reported at studied doses[1][3][4][5][6].